Last reviewed · How we verify

BMN 110 - Weekly — Competitive Intelligence Brief

BMN 110 - Weekly (BMN 110 - Weekly) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Enzyme replacement therapy. Area: Rare genetic metabolic disorder.

phase 3 Enzyme replacement therapy Lysosomal acid lipase (LAL) Rare genetic metabolic disorder Small molecule Live · refreshed every 30 min

Target snapshot

BMN 110 - Weekly (BMN 110 - Weekly) — BioMarin Pharmaceutical. BMN 110 is a recombinant human lysosomal acid lipase (LAL) enzyme replacement therapy that restores deficient enzyme activity in patients with LAL deficiency.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BMN 110 - Weekly TARGET BMN 110 - Weekly BioMarin Pharmaceutical phase 3 Enzyme replacement therapy Lysosomal acid lipase (LAL)
Pegvaliase-Pqpz Pegvaliase-Pqpz University of Missouri-Columbia marketed Enzyme replacement therapy Phenylalanine (substrate); phenylalanine ammonia lyase (active enzyme)
creon 35.000 Ph.U (R) creon 35.000 Ph.U (R) Hospital Clinico Universitario de Santiago marketed Pancreatic enzyme replacement therapy
alpha-1-Proteinase Inhibitor alpha-1-Proteinase Inhibitor Institute for Human Genetics and Biochemistry marketed Protease inhibitor / Enzyme replacement therapy Neutrophil elastase
Panzytrat 25.000 FIP-E units of Lipase Panzytrat 25.000 FIP-E units of Lipase Foundation for Liver Research marketed Pancreatic enzyme replacement therapy Triglycerides and dietary lipids
Cerezyme® / Imiglucerase Cerezyme® / Imiglucerase Sanofi marketed Enzyme replacement therapy Glucocerebrosidase (β-glucosidase)
agalsidase beta (GZ419828) agalsidase beta (GZ419828) Sanofi marketed Enzyme replacement therapy Alpha-galactosidase A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Enzyme replacement therapy class)

  1. BioMarin Pharmaceutical · 5 drugs in this class
  2. Sanofi · 3 drugs in this class
  3. JCR Pharmaceuticals Co., Ltd. · 2 drugs in this class
  4. Genzyme, a Sanofi Company · 2 drugs in this class
  5. Pfizer Inc. · 1 drug in this class
  6. Shire · 1 drug in this class
  7. Alexion Pharmaceuticals, Inc. · 1 drug in this class
  8. University of Missouri-Columbia · 1 drug in this class
  9. Eurofarma Laboratorios S.A. · 1 drug in this class
  10. ISU Abxis Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BMN 110 - Weekly — Competitive Intelligence Brief. https://druglandscape.com/ci/bmn-110-weekly. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: